Formulation and Evaluation of Mucilage-Based Nanoparticles for Effective Delivery of Ezetimibe.

Ume Ruqia Tulain, Arshad Mahmood, Sidra Aslam, Alia Erum, Nadia Shamshad Malik, Ayesha Rashid, Rizwana Kausar, Mohammed S Alqahtani
Author Information
  1. Ume Ruqia Tulain: College of Pharmacy, University of Sargodha, Sargodha, Pakistan.
  2. Arshad Mahmood: College of Pharmacy, Al Ain University, Abu Dhabi Campus, Abu Dhabi, United Arab Emirates.
  3. Sidra Aslam: College of Pharmacy, University of Sargodha, Sargodha, Pakistan.
  4. Alia Erum: College of Pharmacy, University of Sargodha, Sargodha, Pakistan.
  5. Nadia Shamshad Malik: Faculty of Pharmacy, Capital University of Science & Technology, Islamabad, Pakistan. ORCID
  6. Ayesha Rashid: Department of Pharmacy, The Women University Multan, Multan, Pakistan.
  7. Rizwana Kausar: ILM College of Pharmaceutical Sciences, Sargodha, Pakistan.
  8. Mohammed S Alqahtani: Nanobiotechnology Unit, Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. ORCID

Abstract

INTRODUCTION: The aim of current study was to prepare mucilage (LUM) based nanoparticles, capable of encapsulating hydrophobic drug ezetimibe as nanocarriers.
METHODS: Solvent evaporation and nanoprecipitation techniques were used to develop nanoparticles by encapsulating ezetimibe in the articulated matrix of polysaccharide fractions. Developed nanoparticles were characterized to determine the particle size, zeta potential, polydispersibility index (PDI), and entrapment efficiency (EE). Morphology and physicochemical characterization were carried out through SEM, FTIR, PXRD and thermal analysis. Saturation solubility and in vitro release studies were also performed. Safety assessment of ezetimibe loaded nanoparticles was evaluated via oral acute toxicity study.
RESULTS: The mean particle size, zeta potential, PDI and EE for emulsion solvent evaporation were 683.6 nm, -28.3 mV, 0.39, 63.7% and for nanoprecipitation were 637.7 nm, 0.07, -27.1 mV and 80%, respectively. Thermal analysis confirmed enhanced thermal stability, whereas PXRD confirmed amorphous nature of drug. Saturation solubility (p-value <0.05) demonstrated improved solubility of drug when enclosed in linseed nanoparticles. Nanoprecipitation surpasses emulsion solvent evaporation in dissolution test by possessing smaller size. Acute oral toxicity study indicated no significant changes in behavioral, clinical or histopathological parameters of control and experimental groups.
CONCLUSION: The in vitro release of ezetimibe was augmented by enhancing aqueous solubility through devised nanoparticles. Thus, linseed mucilage could act as biopolymer in the fabrication of nanoparticle formulation. The acute oral toxicological investigations provided evidence that LUMNs were safe after oral administration.

Keywords

References

  1. Indian J Pharmacol. 2013 Jan-Feb;45(1):61-5 [PMID: 23543876]
  2. Food Chem. 2019 Nov 30;299:125144 [PMID: 31323440]
  3. Langmuir. 2006 Sep 12;22(19):8178-85 [PMID: 16952259]
  4. J Control Release. 2002 Jul 18;82(1):105-14 [PMID: 12106981]
  5. Microb Pathog. 2018 Feb;115:287-292 [PMID: 29306005]
  6. J Dent. 2007 Mar;35(3):253-8 [PMID: 17045723]
  7. Food Chem. 2016 May 15;199:356-63 [PMID: 26775982]
  8. J Control Release. 2001 Feb 23;70(3):353-63 [PMID: 11182205]
  9. Int J Nanomedicine. 2015 Sep 30;10:6147-59 [PMID: 26491288]
  10. J Cosmet Sci. 2018 May/Jun;69(3):165-173 [PMID: 30052191]
  11. Drug Discov Today. 2012 Jul;17(13-14):784-92 [PMID: 22521664]
  12. Molecules. 2018 Sep 24;23(10): [PMID: 30250012]
  13. Int J Pharm. 2014 Dec 30;477(1-2):431-41 [PMID: 25445523]
  14. Colloids Surf B Biointerfaces. 2010 Jan 1;75(1):1-18 [PMID: 19782542]
  15. J Control Release. 2014 Sep 28;190:31-2 [PMID: 25356469]
  16. Carbohydr Polym. 2016 Jan 20;136:750-6 [PMID: 26572409]
  17. J Control Release. 1999 May 20;59(2):123-32 [PMID: 10332048]
  18. Colloids Surf B Biointerfaces. 2019 Jun 1;178:460-468 [PMID: 30921681]
  19. Pharm Dev Technol. 2019 Jan;24(1):89-98 [PMID: 29307260]
  20. J Control Release. 1998 Jan 2;50(1-3):31-40 [PMID: 9685870]
  21. J Vet Med Sci. 2011 Nov;73(11):1417-23 [PMID: 21712637]
  22. Int J Nanomedicine. 2017 Apr 06;12:2845-2855 [PMID: 28435262]
  23. Int J Pharm. 2008 Feb 28;350(1-2):320-9 [PMID: 17913411]
  24. Saudi Pharm J. 2014 Jul;22(3):219-22 [PMID: 25061407]
  25. Int J Pharm. 2009 Mar 31;370(1-2):202-9 [PMID: 19114097]
  26. Pharm Res. 1994 Dec;11(12):1800-8 [PMID: 7899246]
  27. Toxicol Pathol. 2008 Jan;36(1):43-8 [PMID: 18337220]
  28. J Biomed Mater Res A. 2008 Mar 1;84(3):589-97 [PMID: 17618490]
  29. Pharmacol Rep. 2011;63(6):1335-48 [PMID: 22358082]
  30. Proc (Bayl Univ Med Cent). 2003 Jul;16(3):354-8 [PMID: 16278712]

MeSH Term

Administration, Oral
Drug Carriers
Ezetimibe
Flax
Nanoparticles
Particle Size
Plant Mucilage
Solubility

Chemicals

Drug Carriers
Plant Mucilage
Ezetimibe

Word Cloud

Created with Highcharts 10.0.0nanoparticlesezetimibeoralsolubilitystudymucilagedrugevaporationsizeacutetoxicitylinseedencapsulatinghydrophobicnanoprecipitationparticlezetapotentialPDIEEPXRDthermalanalysisSaturationvitroreleaseemulsionsolventnmmV0confirmedINTRODUCTION:aimcurrentprepareLUMbasedcapablenanocarriersMETHODS:SolventtechniquesuseddeveloparticulatedmatrixpolysaccharidefractionsDevelopedcharacterizeddeterminepolydispersibilityindexentrapmentefficiencyMorphologyphysicochemicalcharacterizationcarriedSEMFTIRstudiesalsoperformedSafetyassessmentloadedevaluatedviaRESULTS:mean6836-28339637%637707-27180%respectivelyThermalenhancedstabilitywhereasamorphousnaturep-value<005demonstratedimprovedenclosedNanoprecipitationsurpassesdissolutiontestpossessingsmallerAcuteindicatedsignificantchangesbehavioralclinicalhistopathologicalparameterscontrolexperimentalgroupsCONCLUSION:augmentedenhancingaqueousdevisedThusactbiopolymerfabricationnanoparticleformulationtoxicologicalinvestigationsprovidedevidenceLUMNssafeadministrationFormulationEvaluationMucilage-BasedNanoparticlesEffectiveDeliveryEzetimibenanocarrier

Similar Articles

Cited By (3)